NCT06963814 Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
| NCT ID | NCT06963814 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | HC Biopharma Inc. |
| Condition | Advanced Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 252 participants |
| Start Date | 2025-07-04 |
| Primary Completion | 2026-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 252 participants in total. It began in 2025-07-04 with a primary completion date of 2026-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an open-label, multicenter Phase 1b clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of HC006 in combination with a PD-1 inhibitor in patients with advanced solid tumors. The trial is divided into two stages: dose-escalation and dose expansion. First, the dose-escalation study is completed to determine the recommended dose for subsequent extension studies, and then the dose expansion study is conducted in the proposed tumors with potential treatment benefits.
Eligibility Criteria
Inclusion Criteria: 1. Fully understand this trial and voluntarily sign the informed consent form; 2. Advanced solid tumors diagnosed by histology or cytopathology; 3. Be able to provide archived (within 2 years after the first treatment with study drug) or fresh tumor tissue samples for relevant biological sample analysis required by the protocol; 4. At least one measurable lesion according to RECIST Version 1.1 (patients with only brain lesion as target lesion are not accepted); 5. Eastern United States Oncology Assistance Group (ECOG) performance status score of 0 or 1; 6. The expected survival time is more than 3 months; 7. Adequate organ and bone marrow function 8. Females of childbearing potential must have a negative blood pregnancy test within 7 days prior to the first dose of investigational product and be non-lactating; Eligible patients of childbearing potential (male and female) must agree to use a reliable method of contraception (hormonal or barrier method or abstinence) with their partner for at least 6 months from signing informed consent until after the last dose of study drug. Women of non-childbearing potential may not undergo pregnancy test and contraception (postmenopausal for at least 1 year or surgically sterilized). Exclusion Criteria: 1. Patients with imaging findings showing tumor invasion of great vessels or unclear demarcation from blood vessels; 2. Patients with combined brain metastasis, meningeal metastasis, spinal cord compression or leptomeningeal disease; 3. Previous treatment with monoclonal antibodies, bispecific antibodies, small molecule compounds and cells targeting CCR8 at any time; 4. Conditions may significantly affect the autoimmune status; 5. Patients with serious, uncontrolled and unrecoverable acute and chronic diseases: 6. Subjects with other malignant tumors within 5 years prior to the first dose of the investigational drug ; 7. Subjects who have undergone major organ surgery (excluding aspiration biopsy) within 4 weeks prior to the first dose of study drug, or have experienced significant trauma, or require elective surgery during the trial;
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06963814 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Advanced Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06963814 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06963814 currently recruiting?
Yes, NCT06963814 is actively recruiting participants. Contact the research team at ke.yao@btyy.com for enrollment information.
Where is the NCT06963814 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06963814 clinical trial?
NCT06963814 is sponsored by HC Biopharma Inc.. The trial plans to enroll 252 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.